search
Back to results

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Primary Purpose

Hypertension, Diastolic Dysfunction

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
valsartan
amlodipine
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, systolic blood pressure, diastolic dysfunction, valsartan, amlodipine

Eligibility Criteria

45 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 45 years or older
  • Male and female patients are eligible. Female patients must be post-menopausal for one year, surgically sterile, or using effective contraceptive methods such as a double barrier method with spermicide, an intra-uterine device, or hormonal contraceptives. Post-menopausal women on a stable dose of hormone replacement therapy (HRT) for at least three (3) months prior to the screening visit are eligible for the study.
  • Uncontrolled systolic hypertension on a maximum of two (2) antihypertensive medications at the time of screening.
  • Echocardiographic ejection fraction ≥50% and evidence of diastolic dysfunction.
  • Provide written informed consent to participate in the study prior to any screening or study procedures
  • Have the ability to communicate well and comply with all study requirements

Exclusion Criteria:

  • Severe hypertension defined as a MSSBP >200 mmHg and/or MSDBP >120 mmHg.
  • History of a secondary cause of hypertension including but not limited to: coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc.
  • Ejection fraction <50 %
  • History of stroke, transient ischemic attack, myocardial infarction, coronary artery bypass graft surgery, or unstable angina pectoris within 6 months of screening
  • Presence of clinically significant ventricular or supraventricular arrhythmias (e.g. atrial fibrillation/flutter)
  • History of congestive heart failure
  • History of diabetes mellitus
  • History of renal impairment with serum creatinine >2.0 mg/dL at screening, history of dialysis, or history of nephritic syndrome
  • Antihypertensive therapy with three (3) or more medications at the time of screening
  • Active and/or treated malignancy of any organ system within twelve (12) months of enrollment, with the exception of localized basal cell carcinoma of the skin
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/ml)
  • Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: barrier method with spermicidal agent, an intrauterine device, hormonal contraceptives, or total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Reliable contraception should be maintained throughout the study
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug including, but not limited to, any of the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active, or active inflammatory bowel syndrome within 12 months prior to Visit 1, currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction regarded as clinically meaningful by the investigator
  • Pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury within 12 months prior to Visit 1
  • Any serum AST or ALT elevation two (2) times the upper limit of normal

Other protocol-defined inclusion/exclusion criteria may apply

Sites / Locations

  • Novartis Investigative Sites

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Standard treatment regimen

Intensive treatment regimen

Arm Description

(Valsartan + Amlodipine to target SBP of < 140 mmHg)

(Valsartan + Amlodipine to target SBP < 130 mm Hg)

Outcomes

Primary Outcome Measures

Change in Lateral Mitral Annular Myocardial Relaxation Velocity
Change from baseline in lateral mitral annular myocardial relaxation velocity (E') at Week 24

Secondary Outcome Measures

Change in Left Atrial Size
Change from baseline in left atrial size at Week 24
Change in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity
Change from baseline in peak E-wave velocity / lateral mitral annular myocardial relaxation velocity (E/E') at Week 24
Percent Change From Baseline in Vascular Stiffness
Percent change from baseline in Vascular Stiffness (measured by radial augmentation index [AI]) at Weeks 8 and 24
Change in Mean Sitting Systolic Blood Pressure (msSBP)
Change from baseline in msSBP at Weeks 8 and 24
Change in Mean Sitting Diastolic Blood Pressure (msDBP)
Change from baseline in msDBP at Weeks 8 and 24
Change in Estimated Central Aortic Pressure
Change from baseline in estimated central aortic pressure at Weeks 8 and 24

Full Information

First Posted
August 30, 2007
Last Updated
April 19, 2012
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00523549
Brief Title
The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
Official Title
A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
January 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of <140 mmHg on the intrinsic diastolic properties of the myocardium in patients with hypertension and echocardiographic evidence of diastolic dysfunction.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Diastolic Dysfunction
Keywords
Hypertension, systolic blood pressure, diastolic dysfunction, valsartan, amlodipine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
229 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard treatment regimen
Arm Type
Experimental
Arm Description
(Valsartan + Amlodipine to target SBP of < 140 mmHg)
Arm Title
Intensive treatment regimen
Arm Type
Experimental
Arm Description
(Valsartan + Amlodipine to target SBP < 130 mm Hg)
Intervention Type
Drug
Intervention Name(s)
valsartan
Other Intervention Name(s)
Diovan
Intervention Description
160 mg or 320 mg tablets once a day
Intervention Type
Drug
Intervention Name(s)
amlodipine
Other Intervention Name(s)
Norvasc
Intervention Description
5 mg or 10 mg tablets once a day
Primary Outcome Measure Information:
Title
Change in Lateral Mitral Annular Myocardial Relaxation Velocity
Description
Change from baseline in lateral mitral annular myocardial relaxation velocity (E') at Week 24
Time Frame
Baseline to 24 weeks after treatment
Secondary Outcome Measure Information:
Title
Change in Left Atrial Size
Description
Change from baseline in left atrial size at Week 24
Time Frame
Baseline to 24 weeks after treatment
Title
Change in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity
Description
Change from baseline in peak E-wave velocity / lateral mitral annular myocardial relaxation velocity (E/E') at Week 24
Time Frame
Baseline to 24 weeks after treatment
Title
Percent Change From Baseline in Vascular Stiffness
Description
Percent change from baseline in Vascular Stiffness (measured by radial augmentation index [AI]) at Weeks 8 and 24
Time Frame
Baseline to 8 and 24 weeks after treatment
Title
Change in Mean Sitting Systolic Blood Pressure (msSBP)
Description
Change from baseline in msSBP at Weeks 8 and 24
Time Frame
Baseline to 8 and 24 weeks after treatment
Title
Change in Mean Sitting Diastolic Blood Pressure (msDBP)
Description
Change from baseline in msDBP at Weeks 8 and 24
Time Frame
Baseline to 8 and 24 weeks after treatment
Title
Change in Estimated Central Aortic Pressure
Description
Change from baseline in estimated central aortic pressure at Weeks 8 and 24
Time Frame
Baseline to 8 and 24 weeks after treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 45 years or older Male and female patients are eligible. Female patients must be post-menopausal for one year, surgically sterile, or using effective contraceptive methods such as a double barrier method with spermicide, an intra-uterine device, or hormonal contraceptives. Post-menopausal women on a stable dose of hormone replacement therapy (HRT) for at least three (3) months prior to the screening visit are eligible for the study. Uncontrolled systolic hypertension on a maximum of two (2) antihypertensive medications at the time of screening. Echocardiographic ejection fraction ≥50% and evidence of diastolic dysfunction. Provide written informed consent to participate in the study prior to any screening or study procedures Have the ability to communicate well and comply with all study requirements Exclusion Criteria: Severe hypertension defined as a MSSBP >200 mmHg and/or MSDBP >120 mmHg. History of a secondary cause of hypertension including but not limited to: coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc. Ejection fraction <50 % History of stroke, transient ischemic attack, myocardial infarction, coronary artery bypass graft surgery, or unstable angina pectoris within 6 months of screening Presence of clinically significant ventricular or supraventricular arrhythmias (e.g. atrial fibrillation/flutter) History of congestive heart failure History of diabetes mellitus History of renal impairment with serum creatinine >2.0 mg/dL at screening, history of dialysis, or history of nephritic syndrome Antihypertensive therapy with three (3) or more medications at the time of screening Active and/or treated malignancy of any organ system within twelve (12) months of enrollment, with the exception of localized basal cell carcinoma of the skin Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/ml) Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: barrier method with spermicidal agent, an intrauterine device, hormonal contraceptives, or total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Reliable contraception should be maintained throughout the study Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug including, but not limited to, any of the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active, or active inflammatory bowel syndrome within 12 months prior to Visit 1, currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction regarded as clinically meaningful by the investigator Pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury within 12 months prior to Visit 1 Any serum AST or ALT elevation two (2) times the upper limit of normal Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Sites
City
USA
State/Province
New Jersey
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
19996069
Citation
Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert RJ, Rocha R, Pitt B; Exforge Intensive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction Investigators. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010 Feb;55(2):241-8. doi: 10.1161/HYPERTENSIONAHA.109.138529. Epub 2009 Dec 7.
Results Reference
result

Learn more about this trial

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

We'll reach out to this number within 24 hrs